
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Kylo-12
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Single-ascending Dose Study of Kylo-12 in Healthy Subjects
Details : Kylo-12 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertriglyceridemia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 20, 2025
Lead Product(s) : Kylo-12
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Kylo-0603
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Escalation Study of Kylo-0603 in Healthy Subjects
Details : Kylo-0603 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : Kylo-0603
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Kylo-11
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Single-ascending Dose Study of Kylo-11 in Healthy Subjects
Details : Kylo-11 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 12, 2024
Lead Product(s) : Kylo-11
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
